Kenji Aoshima

Kenji Aoshima

Auto-generated profile, based on publicly available information

Kenji Aoshima

Division of Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ECErica Carolina
Erica Carolina
YKYoshiki Kuse
Yoshiki Kuse
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
TTTomomi Tadokoro
Tomomi Tadokoro
HTHideki Taniguchi
Hideki Taniguchi
In fetal development, tissue interaction such as the interplay between blood vessel (BV) and epithelial tissue is crucial for organogenesis. Here we recapitulate the spatial arrangement between liver epithelial tissue and the portal vein to observe the formation of intrahepatic bile ducts (BDs) from human induced pluripotent stem cells (hiPSC). We co-culture hiPSC-liver progenitors on the artificial BV consisting of immature smooth muscle cells and endothelial cells, both derived from hiPSCs. After 3 weeks, liver progenitors within hiPSC-BV-incorporated liver organoids (BVLO) differentiate to cholangiocytes and acquire epithelial characteristics, including intercellular junctions, microvilli on the apical membrane, and secretory functions. Furthermore, liver surface transplanted-BVLO temporarily attenuates cholestatic injury symptoms. Single cell RNA sequence analysis suggests that BD interact with the BV in BVLO through TGFβ and Notch pathways. Knocking out JAG1 in hiPSC-BV significantly attenuates bile duct formation, highlighting BVLO potential as a model for Alagille syndrome, a congenital biliary disease. Overall, we develop a novel 3D co-culture method that successfully establishes functional human BDs by emulating liver epithelial-BV interaction.

19 September 2024 in Biomaterials
Verified
Journal Article
Open access
STShunsuke Tabe
Shunsuke Tabe
KTKenta Takeuchi
Kenta Takeuchi
KAKenji Aoshima
Kenji Aoshima
AOAyumu Okumura
Ayumu Okumura
YYYuya Yamamoto
Yuya Yamamoto
HTHideki Taniguchi
Hideki Taniguchi
Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with a poor prognosis. It contains a complex tumor microenvironment (TME) that includes various stromal cell types. Comprehending cellular communications within the TME is difficult due to a lack of research models that can recapitulate human PDAC-TME. Previously, we recapitulated, in part, the PDAC-TME containing a diversity of cancer-associated fibroblasts (CAFs) in vitro. This was done by establishing a PDAC organoid by co-culturing patient-derived cancer cells with human induced pluripotent stem cell (hiPSC)-derived mesenchymal and endothelial cells, which was designated the fused pancreatic cancer organoid (FPCO). We further incorporated macrophages derived from the THP-1 cell line, which are the source of tumor-associated macrophages (TAMs), a major TME component, into FPCO, which was designated M0-FPCO. Bulk RNA sequencing (RNAseq) analysis revealed that macrophages in M0-FPCO (FPCO-Mac) lost their pro-inflammatory features but acquired pro-angiogenic features. Consistently, the formation of an endothelial cell network was enhanced in M0-FPCO. Single-cell RNA-seq (scRNA-seq) analysis revealed that M0-FPCO contained five TAM subpopulations similar to the corresponding TAM in human PDAC tissue in the integrated analysis, including SPP1+-TAM, which has been correlated with tumor angiogenesis and cell proliferation. Focusing on PDAC cells, we found that they could survive longer within the organoid in the presence of TAM. Consistent with the prolonged proliferation and survival of PDAC cells, PDAC subclusters were characterized by proliferative features, such as increased M0-FPCO. Therefore, by establishing a PDAC organoid with macrophages, we recapitulated the diversity of TAMs and identified the role of TAM in endothelial network formation as well as in the modulation of PDAC cell properties. SIGNIFICANCE: PDAC organoids, including macrophages using hiPSC, showed that PDAC-TAM has angiogenic features and contributes to PDAC cell survival.

22 April 2025 in Regenerative Therapy
Verified
Journal Article
Open access
KAKenji Aoshima
Kenji Aoshima
NTNaoki Tanimizu
Naoki Tanimizu
Aside from successfully generating induced pluripotent stem cells from somatic cells, “reprogramming of differentiated cells” is a major technique for obtaining any type of target cells in vitro and in vivo by introducing critical transcription factors and using chemical compound combinations. In addition to these technical aspects, the physiological relevance of reprogramming has been extensively investigated, as growing evidence suggests that cellular reprogramming resulting in dedifferentiation or lineage conversion of a specific type of cell is associated with tissue injury and regeneration. We focus on cellular reprogramming in acute and chronically injured livers and summarize the molecular mechanisms governing the lineage transition between two types of liver epithelial cells, hepatocytes, and cholangiocytes.

9 June 2024 in Regenerative Therapy
Verified
Journal Article
Open access
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
NTNaoki Tanimizu
Naoki Tanimizu
Liver is involved in metabolic reactions, ammonia detoxification, and immunity. Multicellular liver tissue cultures are more desirable for drug screening, disease modeling, and researching transplantation therapy, than hepatocytes monocultures. Hepatocytes monocultures are not stable for long. Further, hepatocyte-like cells induced from pluripotent stem cells and in vivo hepatocytes are functionally dissimilar. Organoid technology circumvents these issues by generating functional ex vivo liver tissue from intrinsic liver progenitor cells and extrinsic stem cells, including pluripotent stem cells. To function as in vivo liver tissue, the liver organoid cells must be arranged precisely in the 3 -dimensional space, closely mimicking in vivo liver tissue. Moreover, for long term functioning, liver organoids must be appropriately vascularized and in contact with neighboring epithelial tissues (e.g., bile canaliculi and intrahepatic bile duct, or intrahepatic and extrahepatic bile ducts). Recent discoveries in liver developmental biology allows one to successfully induce liver component cells and generate organoids. Thus, here, in this review, we summarize the current state of knowledge on liver development with a focus on its application in generating different liver organoids. We also cover the future prospects in creating (functionally and structurally) in vivo-like liver organoids using the current knowledge on liver development. (c) 2024, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/

12 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YYYuya Yamamoto
Yuya Yamamoto
KTKenta Takeuchi
Kenta Takeuchi
STShunsuke Tabe
Shunsuke Tabe
AOAyumu Okumura
Ayumu Okumura
KAKenji Aoshima
Kenji Aoshima
HTHideki Taniguchi
Hideki Taniguchi
Summary: The specific contribution of tissue-resident macrophages (TRMs) to pancreatic ductal adenocarcinoma (PDAC) progression remains unclear. Here, we found that a high abundance of TRM-derived tumor-associated macrophages (TRM-TAMs) is an independent indicator of poor prognosis in patients with PDAC. To elucidate the underlying mechanism, we established an advanced organoid platform (iMac-FPCO), which incorporates macrophages derived from human induced pluripotent stem cells to reflect the differentiation process of TRMs. Single-cell transcriptomic analysis revealed this model recapitulates the transcriptional identity of TRM-TAMs in patient tissue. We demonstrated that TRM-TAMs drive cancer cell proliferation, while maintaining chemoresistance, and identified TRM-derived insulin-like growth factor 1 (IGF1) as the critical mediator. This result provides a rationale for why previous trials targeting IGF1 receptor (IGF1R) failed to improve survival in unselected patient populations. We hypothesize that stratifying patients by TRM-TAM abundance could help identify a responsive subgroup, thereby reviving IGF1R-targeted therapy as a viable treatment for PDAC.